Biology Reference
In-Depth Information
Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M,
Gross M, Gaeta F, Johnson K, Lolis EJ (2010) Allosteric inhibition of macrophage
migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 107:11313-11318
Choi SH, Sakamoto T, Fukutomi O, Inagaki N, Matsuura N, Nagai H, Koda A (1989) Pharmaco-
logical study of phospholipase A2-induced histamine release from rat peritoneal mast cells.
J Pharmacobiodyn 12:517-522
Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayers JG, Creemers JP,
Schultze-Werninghaus G, Brabilla C, Barnes NC (2001) Cilomilast, a selective phosphodies-
terase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease:
a randomised, dose-ranging study. Lancet 358:265-270
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases:
essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A (2009) Low-dose
theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD.
Thorax 64:424-429
Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R (1985) Adenosine;
a physiologic modulator of superoxide anion generation by human neutrophils: Adenosine
acts via A2 receptor on neutrophils. J Immunol 135:1366-1371
Culpitt SV, de Matos C, Russell RE, Rogers DLE, DF BPJ (2002) Effect of theophylline
on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 165:1371-1376
Danto S, Wei GC, Gill J et al (2007a) A randomized, double-blind, parallel group, six-week study
of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with persistent
asthma. Am J Respir Crit Care Med 175:A485
Danto S, Wei GC, Gill J et al (2007b) A randomized, double-blind, parallel group, six-week study
of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD.
Am J Respir Crit Care Med 175:A131
De Mey C, Hauns B, Knoerzer D, Grossmann M, Haverkamp W, Bethke TD, Hermann R (2006a)
Roflumilast does not potentiate tachycardia associated with formoterol. Proc Am Thorac Soc
3:A112
De Mey C, Hauns B, Lahu G, Reutter F, Knoerzer D, Grossmann M, Haverkamp W, Bethke TD,
Hermann R (2006b) Repeated-dose co-administration of roflumilast and formoterol does not
alter the pharmacokinetics of either drug. Proc Am Thorac Soc 3:A113
Draheim R, Egerland U, Rundfeldt C (2004) Anti-inflammatory potential of the selective
phosphodiesterase 4 inhibitor N-(3, 5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-
indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol
Exp Ther 308:555-663
Eckermann G, Lahu G, Nassr N, Bethke TD (2011) Absence of pharmacokinetic interaction
between roflumilast and digoxin in healthy adults. J Clin Pharmacol (in press)
Engelstaetter R, Wingertzahn M, Schmid-Wirlitsch C, Bredenbroeker D, Leichtl S, Wurst W
(2002). Roflumilast, an investigational oral, once daily, phosphodiesterase-4 inhibitor, did not
exhibit acute bronchodilatory activity after a single dose. American College of Allergy,
Asthma and Immunology (ACAAI), Annual Conference, Boston 2004
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF
(2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with
long-acting bronchodilators: two randomised clinical trials. Lancet 374:695-703
Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H, Kikuchi S, Tashiro K, Suzumura
A, Ishii N, Sugamura K, Nakashima I, Itoyama Y (2004) Ibudilast, a nonselective phosphodi-
esterase inhibitor, regulates Th1/Th2 balance of NKT cell subset in multiple sclerosis. Mult
Scler 10:494-498
Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, Wolf R, Gerlach W,
Jaklitsch H, Sastre-y-Hern´ndez M et al (1992) A multicenter double-blind study of three
